Inside the research
Avantor, Inc.
AVTR Research profile · latest available data
Price overview
$15.25
▼ -0.13 (-0.8%)
| 52w hi | $15.86 |
|---|---|
| 52w lo | $7.41 |
| Vol | 6.53M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.31
| Short | +0.64 |
|---|---|
| Medium | +0.39 |
| Long | -0.51 |
computed 2026-09-27
Key fundamentals
Avantor, Inc.
Healthcare · Medical Instruments & Supplies
| Market cap | $10.31B |
|---|---|
| Enterprise value | $13.71B |
| Forward P/E | 17.30x |
| EV / EBITDA | 14.52x |
| P / S (ttm) | 1.57x |
| Profit margin | -8.8% |
| Return on equity | -9.7% |
| Revenue growth | +0.5% |
| Earnings growth | -37.4% |
| Debt / equity | 65.68 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | -0.14 | |
| Sector | +0.08 | |
| Technical | +0.42 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Risk Metrics
| Beta vs SPX | 1.03 |
|---|---|
| Corr SPX | 0.34 |
| Annual vol | 48.8% |
| Annual ret | -16.3% |
| Sharpe | -0.33 |
| Max DD | -72.1% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $9.92 |
|---|---|
| High / Low | $19.00 / $7.00 |
| Median | $9.00 |
| Analysts | 13 |
| Strong Buy | 0 | |
|---|---|---|
| Buy | 3 | |
| Hold | 10 | |
| Sell | 1 | |
| Strong Sell | 1 |
Recent rating actions
| 2026-04-30 | Evercore ISI Group | → In-Line |
| 2026-04-30 | Citigroup | → Neutral |
| 2026-04-15 | Barclays | → Underweight |
| 2026-04-06 | Evercore ISI Group | → In-Line |
| 2026-03-06 | Barclays | → Underweight |
| 2026-02-13 | Wells Fargo | → Overweight |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-29 | Earnings Release, Exhibits | read |
| 2026-07-17 | Material Agreement, Material Obligation… | read |
| 2026-05-12 | Shareholder Vote, Exhibits | read |
| 2026-04-29 | Earnings Release, Exhibits | read |
| 2026-04-23 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-04-01 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-02-11 | Earnings Release, Reg FD Disclosure… | read |
| 2025-12-18 | Officer / Director Change, Reg FD Disclosure… | read |
| 2025-12-04 | Officer / Director Change, Reg FD Disclosure… | read |
| 2025-11-10 | Officer / Director Change, Reg FD Disclosure… | read |
| 2025-10-29 | Earnings Release, Exhibits | read |
| 2025-10-14 | Material Agreement, Termination of Agreement… | read |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 8 |
| Top-5 share | 98.3% |
| HHI | 2,981 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $213.57M | 21.57M |
| AQR Capital Management | $115.11M | 11.63M |
| Fidelity / FMR LLC | $77.67M | 7.85M |
| Capital Research / Capital World | $56.16M | 5.67M |
| Millennium Management | $7.46M | 753.58K |
| Citadel Advisors | $5.08M | 512.95K |
| Bridgewater Associates | $2.98M | 301.22K |
| T. Rowe Price Group | $6.83K | 689.85K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2019–2025 · 6 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $6.55B | +34.2% | |
| Gross profit | $2.14B | +37.2% | |
| Operating income | $696.40M | +4.8% | |
| Net income | $321.10M | +53.4% | |
| Cash from ops | $840.80M | +18.9% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $15.33 | $15.36 | $15.07 | $15.25 | 6.53M |
| Sep 24 | $14.72 | $15.43 | $14.67 | $15.38 | 7.72M |
| Sep 23 | $14.95 | $15.14 | $14.72 | $14.76 | 10.57M |
| Sep 22 | $15.13 | $15.32 | $14.91 | $14.94 | 11.16M |
| Sep 21 | $15.39 | $15.59 | $15.04 | $15.10 | 9.19M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →